ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Edgewise Therapeutics Inc

Edgewise Therapeutics Inc (EWTX)

18.98
0.25
(1.33%)
At close: July 26 4:00PM
19.28
0.30
( 1.58% )
After Hours: 5:34PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
19.28
Bid
18.73
Ask
19.00
Volume
997,783
18.73 Day's Range 20.26
5.12 52 Week Range 23.50
Market Cap
Previous Close
18.73
Open
18.80
Last Trade
87
@
18.75
Last Trade Time
17:37:20
Financial Volume
$ 19,080,131
VWAP
19.1225
Average Volume (3m)
722,261
Shares Outstanding
93,398,767
Dividend Yield
-
PE Ratio
-17.69
Earnings Per Share (EPS)
-1.07
Revenue
-
Net Profit
-100.16M

About Edgewise Therapeutics Inc

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Edgewise Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EWTX. The last closing price for Edgewise Therapeutics was $18.73. Over the last year, Edgewise Therapeutics shares have traded in a share price range of $ 5.12 to $ 23.50.

Edgewise Therapeutics currently has 93,398,767 shares outstanding. The market capitalization of Edgewise Therapeutics is $1.75 billion. Edgewise Therapeutics has a price to earnings ratio (PE ratio) of -17.69.

EWTX Latest News

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare...

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – – Positive interim topline data for DUNE trial of sevasemten...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.68-8.0152671755720.9622.22518.4193793020.30312623CS
41.297.1706503613117.9923.517.5185649920.92604179CS
12-0.46-2.3302938196619.7423.515.8772226119.06896633CS
263.2720.424734540916.0123.514.973627118.08715425CS
5212.29175.822603726.9923.55.1260077814.75325551CS
156-0.66-3.3099297893719.9423.55.1235463913.31375655CS
260-7.72-28.59259259262740.495.1234151014.16256571CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CGTXCognition Therapeutics Inc
$ 3.49
(47.26%)
4.67M
RNAZTransCode Therapeutics Inc
$ 0.365
(23.48%)
6.79M
NAMSNewAmsterdam Pharma Company NV
$ 22.49
(19.25%)
18.82k
YIBOPlanet Image International Ltd
$ 3.40
(16.64%)
62.92k
YYGHYY Group Holding Ltd
$ 0.84
(14.60%)
743
VTVTvTv Therapeutics Inc
$ 13.0022
(-38.67%)
33.35k
CEROCERo Therapeutics Holdings Inc
$ 0.169
(-33.98%)
3.64M
TGLTreasure Global Inc
$ 1.40
(-24.32%)
54.67k
LUXHLuxUrban Hotels Inc
$ 0.1586
(-16.96%)
1.31M
GVHGlobavend Holdings Ltd
$ 0.6302
(-13.06%)
47.77k
SLNASelina Hospitality PLC
$ 0.0265
(-11.67%)
25.19M
RNAZTransCode Therapeutics Inc
$ 0.365
(23.48%)
6.79M
CGTXCognition Therapeutics Inc
$ 3.49
(47.26%)
4.67M
TLTiShares 20 plus Year Treasury Bond
$ 92.90
(-0.10%)
3.91M
CEROCERo Therapeutics Holdings Inc
$ 0.169
(-33.98%)
3.64M

EWTX Discussion

View Posts
Whalatane Whalatane 1 day ago
Sizable sell off despite this again today
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating
Kiwi
👍️0
Whalatane Whalatane 2 weeks ago
I used to own CYTK and think I sold it because of this ...from the CYTK trial Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be
👍️0
rosemountbomber rosemountbomber 3 weeks ago
Thanks for all the info Kiwi. Been a long busy day so I will have to do some more DD on this one but it appears to be promising. The fact that the drug does not have the ejection fraction problem is important in my books. This could be another CYTK. My one worry is that it has had quite a sunup in 2024 already and hopefully not everything is priced in yet.
👍️0
Whalatane Whalatane 3 weeks ago
Before EWTX there was MYOK in HCM ...bt out at $225 a share .
EWTX hired some MYOK folks after this buyout
https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx

Kiwi
👍️0
Whalatane Whalatane 3 weeks ago
Watch for a technical breakout as market anticipates the P1 HCM data
Mavacamten is I think the drug currently approved for HCM ( heart contractibility problems ) . The problem is it lowers ejection fraction ( the pump out movement ) to low for about 20% of the patients so it has a REMS rating limiting its use.
EWTX EDG-5506 works the same way but without the ejection fraction problem

Data due this Qt ( Q3 )

Kiwi
👍️0
Whalatane Whalatane 4 weeks ago
Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics ( EWTX ) with a Overweight and maintains $48 price target.

Kiwi
👍️0
Whalatane Whalatane 4 weeks ago
RMB. some HCM P1 data due late Aug / Sept ...
Kiwi
👍️0
Whalatane Whalatane 3 months ago
RMB. I think we are due for data from the LYNX trial
, Edgewise Therapeutics expects to report 3-month data from the Phase 2 LYNX trial for EDG-5506 in the second quarter of 2024. The LYNX trial is a Phase 2 dose-ranging study to evaluate the safety and efficacy of EDG-5506 in patients with Duchenne muscular dystrophy (DMD).

New high today

Kiwi
👍️0
Whalatane Whalatane 3 months ago
Wedbush Reiterates Outperform on Edgewise Therapeutics, Maintains $26 Price Target

I'm surprised stock didn't do better on recent P 2 data ...which was supposed to " de risk " their program

Kiwi
👍️0
Whalatane Whalatane 5 months ago
BOULDER, Colo., February 13, 2024--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.
EDG-5506 is an investigational orally administered small molecule designed to prevent contraction-induced muscle damage in dystrophinopathies, including Duchenne and Becker muscular dystrophy (Becker).
The FDA previously granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne and Becker, Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne, and Fast Track designation for the treatment of Becker.
---------------
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. for what its worth ...both stocks I mentioned are now "technically " over bought ...so some pull back near term is likely
jmo
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. EWTX up 21 % in past week. ( since your post )
VERA ,,,which I think U saw me posting on at the AUPH board ...up 28%
Both I think at 52 wk highs

Usually I find it best to initiate small positions ...follow ..and then if the data still looks good , add on a pullback due to some unrelated event .
Both of these Co's have a lot of data coming out in 2024

Kiwi
👍️0
Monksdream Monksdream 6 months ago
EWTX new 52 week high
👍️0
Monksdream Monksdream 6 months ago
EWTX new 52 week high
👍️0
Whalatane Whalatane 6 months ago
Jonathan C. Fox, M.D., Ph.D., FACC
DIRECTOR
Jonathan C. Fox, M.D., Ph.D., FACC, serves as a member of our board of directors and is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical stage biotechnology company developing novel, genetically targeted therapies. Prior to that, Dr. Fox served as the chief medical officer of MyoKardia, Inc. Additionally, he worked as a consultant at Nigel-Montgomery, LLC, and held various senior R&D positions successively at SmithKline Beecham, Merck Research Laboratories and AstraZeneca. He was also on the faculty of the University of Pennsylvania School of Medicine. Dr. Fox serves on the board at ML BioSolutions and is a trustee of the Lankenau Institute for Medical Research. He is currently an adjunct Professor of Medicine at the Stanford University Cardiovascular Institute. He received his A.B. in biology, his Ph.D. in experimental pathology and his M.D. from the University of Chicago, and completed his training in Internal Medicine and Cardiology at Duke University. Dr. Fox is ABIM Certified in Cardiovascular Diseases and is a Fellow of the American College of Cardiology.


MyoKardia was bt out by BMS
Kiwi
👍️0
Whalatane Whalatane 6 months ago
RMB. You might look at TNYA also ...similar space. Ceo is one very smart guy and is backed by the Column group ( smart team )
Early days tho .
EWTX is far further along

BOTH are high speculative ...so.....etc
Kiwi
👍️0
rosemountbomber rosemountbomber 6 months ago
Kiwi you have peaked my interest in EWTX

The opportunity seems to be here, but I will try to exhibit something I rarely do, namely; patience.

It has risen a bunch in a short time and I hope to pick some up after a bit of a retracement.
👍️0
Whalatane Whalatane 6 months ago
EWTX. Best Co I've seen in this area since MYOK ...which was eventually bt out .
Kiwi
👍️0
Whalatane Whalatane 6 months ago
Impressive presentation at JPM 2024 . Fast tracked but the earliest they are likely to have an approved drug is early 2026...if all goes well
Kiwi
👍️0
goodfree goodfree 3 years ago
Looks like we may have hit the bottom lol
👍️0
goodfree goodfree 3 years ago
Jumped in at $30 today hope we have a good run here
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.
👍️0
crudeoil24 crudeoil24 3 years ago
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The Company is principally focused on discovering, developing and commercializing treatments for rare muscle disorders. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The Company's lead candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). The Company's research programs include EDG-6289, EDG-002 and EDG-003.
👍️0